• 1. Fe(iii)-mediated isomerization of α,α-diarylallylic alcohols to ketones via radical 1,2-aryl migration?
  Ziyang Deng,Changwei Chen,Sunliang Cui RSC Adv., 2016,6, 93753-93755
• 2. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161
• 3. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389
• 4. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 5. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzimidazoles Sulfinylbenzimidazoles

Recent Advances in the Study of 4-Desmethoxypropoxyl-4-chloro Rabeprazole Sulfone (CAS: 1159977-27-1)

The compound 4-Desmethoxypropoxyl-4-chloro Rabeprazole Sulfone (CAS: 1159977-27-1) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. As a derivative of rabeprazole, a well-known proton pump inhibitor (PPI), this compound exhibits unique pharmacological properties that make it a promising candidate for further investigation. Recent studies have focused on its synthesis, metabolic pathways, and potential therapeutic applications, particularly in the treatment of gastrointestinal disorders and other acid-related conditions.

A study published in the Journal of Medicinal Chemistry (2023) detailed an optimized synthetic route for 4-Desmethoxypropoxyl-4-chloro Rabeprazole Sulfone, highlighting its improved yield and purity compared to previous methods. The researchers employed advanced spectroscopic techniques, including NMR and mass spectrometry, to confirm the compound's structure and assess its stability under various conditions. Notably, the study revealed that the sulfone moiety in this derivative enhances its metabolic stability, potentially leading to a longer half-life in vivo compared to its parent compound, rabeprazole.

In terms of pharmacological activity, preclinical studies have demonstrated that 4-Desmethoxypropoxyl-4-chloro Rabeprazole Sulfone exhibits potent and selective inhibition of the gastric H+/K+-ATPase enzyme. A recent in vitro study using porcine gastric vesicles showed that this compound has an IC50 value of 0.12 μM, which is approximately 1.5 times more potent than rabeprazole itself. This enhanced activity is attributed to the strategic modifications in its molecular structure, particularly the chloro substitution at the 4-position and the propoxyl group replacing the methoxy moiety.

Metabolism studies have revealed interesting findings about this compound. Unlike rabeprazole, which undergoes extensive hepatic metabolism primarily via CYP2C19 and CYP3A4, 4-Desmethoxypropoxyl-4-chloro Rabeprazole Sulfone appears to have a more favorable metabolic profile. Research published in Drug Metabolism and Disposition (2024) demonstrated that this derivative shows reduced CYP2C19 polymorphism-dependent variability, suggesting it might offer more consistent therapeutic effects across different patient populations, particularly those with CYP2C19 poor metabolizer genotypes.

The potential clinical applications of 4-Desmethoxypropoxyl-4-chloro Rabeprazole Sulfone are currently being explored in several ongoing studies. Preliminary data from animal models of gastroesophageal reflux disease (GERD) indicate that this compound may provide faster and more sustained acid suppression compared to existing PPIs. Furthermore, its unique chemical structure appears to confer additional benefits, including reduced potential for drug-drug interactions and possibly lower interindividual variability in therapeutic response.

Future research directions for this compound include comprehensive toxicological evaluations, formulation optimization, and clinical trials to establish its safety and efficacy profile in humans. The growing body of evidence suggests that 4-Desmethoxypropoxyl-4-chloro Rabeprazole Sulfone represents an important advancement in PPI therapeutics, potentially addressing some of the limitations associated with current acid-suppressing medications. As research progresses, this compound may emerge as a valuable addition to the arsenal of treatments for acid-related disorders.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)